CA2884000C - Method for culturing mesenchymal stem cells - Google Patents
Method for culturing mesenchymal stem cells Download PDFInfo
- Publication number
- CA2884000C CA2884000C CA2884000A CA2884000A CA2884000C CA 2884000 C CA2884000 C CA 2884000C CA 2884000 A CA2884000 A CA 2884000A CA 2884000 A CA2884000 A CA 2884000A CA 2884000 C CA2884000 C CA 2884000C
- Authority
- CA
- Canada
- Prior art keywords
- stem cells
- mesenchymal stem
- medium
- cells
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000012258 culturing Methods 0.000 title claims abstract description 36
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000011575 calcium Substances 0.000 claims abstract description 61
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 61
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000011777 magnesium Substances 0.000 claims abstract description 32
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 32
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000001301 oxygen Substances 0.000 claims abstract description 26
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 26
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 24
- 210000004700 fetal blood Anatomy 0.000 claims description 70
- 239000002609 medium Substances 0.000 claims description 43
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 13
- 239000012091 fetal bovine serum Substances 0.000 claims description 13
- 210000003954 umbilical cord Anatomy 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 239000007640 basal medium Substances 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000515 tooth Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 128
- 230000002062 proliferating effect Effects 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 17
- 210000000845 cartilage Anatomy 0.000 abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 abstract description 11
- 230000005847 immunogenicity Effects 0.000 abstract description 10
- 230000035899 viability Effects 0.000 abstract description 9
- 102000004127 Cytokines Human genes 0.000 abstract description 7
- 108090000695 Cytokines Proteins 0.000 abstract description 7
- 230000001172 regenerating effect Effects 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000001186 cumulative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000009758 senescence Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 101100202924 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-2 gene Proteins 0.000 description 8
- 230000002648 chondrogenic effect Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 229960002986 dinoprostone Drugs 0.000 description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 230000002188 osteogenic effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100022464 5'-nucleotidase Human genes 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102100037241 Endoglin Human genes 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 230000018491 positive regulation of cytokine secretion Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- DAQHMCWYXJEOCG-UHFFFAOYSA-N 2-oxopropanoic acid;sodium Chemical compound [Na].CC(=O)C(O)=O DAQHMCWYXJEOCG-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KIWIFIXMWIMRBZ-UHFFFAOYSA-L 4-benzamido-2-methoxy-5-methylbenzenediazonium;dichlorozinc;dichloride Chemical compound [Cl-].[Cl-].Cl[Zn]Cl.C1=C([N+]#N)C(OC)=CC(NC(=O)C=2C=CC=CC=2)=C1C.C1=C([N+]#N)C(OC)=CC(NC(=O)C=2C=CC=CC=2)=C1C KIWIFIXMWIMRBZ-UHFFFAOYSA-L 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0097193 | 2012-09-03 | ||
| KR1020120097193A KR101532556B1 (ko) | 2012-09-03 | 2012-09-03 | 간엽줄기세포의 배양 방법 |
| PCT/KR2013/007891 WO2014035215A1 (en) | 2012-09-03 | 2013-09-02 | Method for culturing mesenchymal stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2884000A1 CA2884000A1 (en) | 2014-03-06 |
| CA2884000C true CA2884000C (en) | 2021-08-24 |
Family
ID=50183937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2884000A Active CA2884000C (en) | 2012-09-03 | 2013-09-02 | Method for culturing mesenchymal stem cells |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9580687B2 (enExample) |
| EP (1) | EP2893001B1 (enExample) |
| JP (1) | JP6478243B2 (enExample) |
| KR (1) | KR101532556B1 (enExample) |
| CN (1) | CN104781394B (enExample) |
| AU (1) | AU2013309642B2 (enExample) |
| CA (1) | CA2884000C (enExample) |
| DK (1) | DK2893001T3 (enExample) |
| ES (1) | ES2755802T3 (enExample) |
| IN (1) | IN2015DN01737A (enExample) |
| PL (1) | PL2893001T3 (enExample) |
| PT (1) | PT2893001T (enExample) |
| WO (1) | WO2014035215A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015170347A2 (en) * | 2014-05-09 | 2015-11-12 | Reelabs Private Limited | Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders |
| JP6519727B2 (ja) * | 2014-09-17 | 2019-05-29 | 国立大学法人山口大学 | 間葉系幹細胞の培養方法、および肝機能障害用治療剤の製造方法 |
| US11000694B2 (en) | 2014-10-24 | 2021-05-11 | The Board Of Trustees Of The University Of Illinois | Use of lasers for treating and reversing fibrosis |
| US10287551B2 (en) * | 2014-10-29 | 2019-05-14 | R Bio Co., Ltd. | Medium composition for culturing stem cells |
| CN105748514A (zh) * | 2015-01-05 | 2016-07-13 | 洪士杰 | 用于治疗肝脏疾病的间叶干细胞 |
| WO2016131430A1 (en) * | 2015-02-20 | 2016-08-25 | Shih-Chieh Hung | Use of mesenchymal stem cells in treating osteoarthritis |
| WO2016184427A1 (zh) * | 2015-05-21 | 2016-11-24 | 中国科学院上海生命科学研究院 | 低氧处理的间充质干细胞及其应用 |
| KR101960592B1 (ko) * | 2016-03-09 | 2019-03-21 | 울산대학교 산학협력단 | Jak1 억제제를 유효성분으로 포함하는 줄기세포의 증식, 분화 촉진 또는 노화 억제용 조성물 |
| RU2018137547A (ru) * | 2016-03-31 | 2020-04-30 | Санбио, Инк. | Среда, способы, клетки и секретируемые факторы для культуры стволовых клеток и терапии |
| WO2018226640A1 (en) * | 2017-06-05 | 2018-12-13 | The Regents Of The University Of The University Of California | Compositions for treating retinal diseases and methods for making and using them |
| JP7173007B2 (ja) | 2017-06-27 | 2022-11-16 | 味の素株式会社 | リボフラビン誘導体含有培地 |
| CN107384858A (zh) * | 2017-08-17 | 2017-11-24 | 成都康景生物科技有限公司 | 一种缺氧耐受型间充质干细胞的制备方法及其应用 |
| CN109666631A (zh) * | 2017-10-17 | 2019-04-23 | 澳门大学 | 增强干细胞活性的培养方法、应用以及用于治疗中枢神经疾病的制剂、制备方法及治疗方法 |
| CN109706115B (zh) * | 2017-10-26 | 2023-05-30 | 中国医科大学 | 一种小鼠骨髓间充质干细胞细胞系的构建方法 |
| CN108359637B (zh) * | 2018-02-14 | 2021-09-28 | 浙江生创精准医疗科技有限公司 | 一种宫血干细胞快速扩增的方法 |
| CN109517786B (zh) * | 2018-10-18 | 2022-06-17 | 广州元帅生物科技有限公司 | 一种具有修复功能的多能干细胞制剂及其应用 |
| US20220348880A1 (en) * | 2019-08-30 | 2022-11-03 | The Texas A&M University System | Xenogen-Free Mesenchymal Stem Cell Compositions and Methods of Use |
| WO2022004938A1 (ko) * | 2020-06-30 | 2022-01-06 | 주식회사 미래셀바이오 | 유사 중간엽 줄기세포의 제조방법 |
| CN112147340B (zh) * | 2020-09-30 | 2024-03-08 | 北京银丰鼎诚生物工程技术有限公司 | 一种神经干细胞免疫调节功能的检测方法 |
| CN112375733B (zh) * | 2020-11-03 | 2022-09-02 | 中国人民解放军陆军军医大学第一附属医院 | 可增进间充质干细胞干细胞性的植物血凝素及其在间充质干细胞扩增培养中的应用 |
| KR102435452B1 (ko) * | 2020-11-11 | 2022-09-07 | 이엔셀 주식회사 | 노화가 감소되고 줄기세포능이 보존된 초기 중간엽 줄기세포, 및 그 배양방법 |
| CN113502261B (zh) * | 2021-07-16 | 2023-08-29 | 上海东方星际干细胞科技有限公司 | 一种能高效分化成脂的规模化3d低氧间充质干细胞培养体系 |
| CN116218770B (zh) * | 2022-12-30 | 2023-11-24 | 苏州科为康生物医药科技有限公司 | 一种间充质干细胞的制备方法和应用 |
| CN117660325B (zh) * | 2024-01-31 | 2024-04-19 | 苏州科为康生物医药科技有限公司 | 一种制备脐带血msc的培养基及其方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4959916B2 (ja) | 2001-08-14 | 2012-06-27 | メディポスト・カンパニー・リミテッド | 関節軟骨損傷治療用組成物 |
| US20030143207A1 (en) * | 2001-10-18 | 2003-07-31 | Livesey Stephen A. | Remodeling of tissues and organ |
| WO2003070922A1 (en) | 2002-02-19 | 2003-08-28 | Medipost Co., Ltd. | Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood, and differentiation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues |
| EP1539934A2 (en) * | 2002-07-30 | 2005-06-15 | Tigenix N.V. | Compositions comprising muscle progenitor cells and uses thereof |
| CA2526845A1 (en) * | 2003-06-06 | 2005-03-31 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
| JP2006055106A (ja) * | 2004-08-23 | 2006-03-02 | National Institute Of Advanced Industrial & Technology | ヒト血清培地を用いるヒト骨髄由来間葉系幹細胞培養法 |
| EP2471907B1 (en) * | 2005-12-29 | 2018-09-26 | Celularity, Inc. | Placental stem cell populations |
| US20070178073A1 (en) * | 2006-02-01 | 2007-08-02 | Samsung Life Public Welfare Foundation | Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease |
| EP2120977B1 (en) * | 2007-02-12 | 2013-05-15 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
| US8114668B2 (en) * | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
| CN101755046B (zh) * | 2007-07-20 | 2012-08-08 | 东国大学校产学协力团 | 采用间充质干细胞制备真皮乳头组织的方法 |
| GB0715648D0 (en) | 2007-08-10 | 2007-09-19 | Cambridge Silicon Radio Ltd | Channel decoding using similarity matching |
| ATE479741T1 (de) * | 2007-09-21 | 2010-09-15 | Univ Leipzig | Zellkulturenmedium und verfahren zur kultivierung von stammzellen und vorläuferzellen |
| US20100330047A1 (en) * | 2009-06-26 | 2010-12-30 | Life & Light Ltd. | Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor |
| KR101243276B1 (ko) * | 2009-10-08 | 2013-03-13 | 서울대학교병원 | 인간 지방 줄기세포의 고활성을 유도하는 방법 및 배지 |
| EP2602310B1 (en) * | 2010-08-03 | 2020-01-22 | Sapporo Medical University | Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient |
| US20120052577A1 (en) | 2010-08-31 | 2012-03-01 | The Regents Of The University Of California | Culture system for stem cell propagation and neural and oligodendrocyte specification |
-
2012
- 2012-09-03 KR KR1020120097193A patent/KR101532556B1/ko active Active
-
2013
- 2013-09-02 PL PL13833872T patent/PL2893001T3/pl unknown
- 2013-09-02 WO PCT/KR2013/007891 patent/WO2014035215A1/en not_active Ceased
- 2013-09-02 CA CA2884000A patent/CA2884000C/en active Active
- 2013-09-02 AU AU2013309642A patent/AU2013309642B2/en active Active
- 2013-09-02 PT PT138338728T patent/PT2893001T/pt unknown
- 2013-09-02 IN IN1737DEN2015 patent/IN2015DN01737A/en unknown
- 2013-09-02 DK DK13833872T patent/DK2893001T3/da active
- 2013-09-02 ES ES13833872T patent/ES2755802T3/es active Active
- 2013-09-02 CN CN201380045750.4A patent/CN104781394B/zh active Active
- 2013-09-02 US US14/425,220 patent/US9580687B2/en active Active
- 2013-09-02 EP EP13833872.8A patent/EP2893001B1/en active Active
- 2013-09-02 JP JP2015529690A patent/JP6478243B2/ja active Active
-
2017
- 2017-01-11 US US15/403,457 patent/US10294456B2/en active Active
-
2019
- 2019-03-29 US US16/370,102 patent/US11332715B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190218517A1 (en) | 2019-07-18 |
| EP2893001B1 (en) | 2019-10-30 |
| AU2013309642B2 (en) | 2018-10-25 |
| PL2893001T3 (pl) | 2020-03-31 |
| US9580687B2 (en) | 2017-02-28 |
| WO2014035215A1 (en) | 2014-03-06 |
| AU2013309642A1 (en) | 2015-03-26 |
| PT2893001T (pt) | 2019-12-09 |
| US11332715B2 (en) | 2022-05-17 |
| CN104781394A (zh) | 2015-07-15 |
| JP6478243B2 (ja) | 2019-03-06 |
| DK2893001T3 (da) | 2019-12-02 |
| CN104781394B (zh) | 2017-12-12 |
| ES2755802T3 (es) | 2020-04-23 |
| KR20140030703A (ko) | 2014-03-12 |
| JP2015532596A (ja) | 2015-11-12 |
| KR101532556B1 (ko) | 2015-06-30 |
| US10294456B2 (en) | 2019-05-21 |
| US20170191036A1 (en) | 2017-07-06 |
| IN2015DN01737A (enExample) | 2015-05-29 |
| EP2893001A4 (en) | 2016-03-09 |
| EP2893001A1 (en) | 2015-07-15 |
| US20150284686A1 (en) | 2015-10-08 |
| CA2884000A1 (en) | 2014-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2884000C (en) | Method for culturing mesenchymal stem cells | |
| WO2014046417A1 (en) | Method for preparing mesenchymal stem cell aggregates | |
| US20100330047A1 (en) | Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor | |
| AU2014315919B2 (en) | Method for culturing mesenchymal stem cells according to cell size | |
| US20180187158A1 (en) | Multifunctional immature dental pulp stem cells and therapeutic applications | |
| CN114540266A (zh) | 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥 | |
| CN112469815A (zh) | 牙髓来源细胞的制造方法 | |
| WO2006001428A1 (ja) | 羊膜由来細胞の分化誘導方法及びその利用 | |
| WO2012133948A1 (ja) | 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物 | |
| JP2009536163A (ja) | 免疫学的寛容および調節性前駆細胞 | |
| CN103459590A (zh) | 可由机体的脐带或脂肪组织分离的多能干细胞 | |
| KR20120006386A (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
| US20200291358A1 (en) | Stem cell derived from young pig and method for producing same | |
| EP4599834A1 (en) | Agent for treating or preventing cerebral palsy | |
| US20250283045A1 (en) | Dental pulp stem cell population | |
| KR100641684B1 (ko) | 지방조직에서 분리한 세포를 포함하는 조혈모세포의 골수안착능 증가활성제 | |
| WO2024128222A1 (ja) | 組成物およびその利用 | |
| WO2024128224A1 (ja) | 間葉系幹細胞の脂肪細胞への分化能を増幅させるための組成物 | |
| HK40038967A (en) | Method for producing dental pulp-derived cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180726 |